65 related articles for article (PubMed ID: 24508841)
21. Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity.
Nguyen-Tan PF; Zhang Q; Ang KK; Weber RS; Rosenthal DI; Soulieres D; Kim H; Silverman C; Raben A; Galloway TJ; Fortin A; Gore E; Westra WH; Chung CH; Jordan RC; Gillison ML; List M; Le QT
J Clin Oncol; 2014 Dec; 32(34):3858-66. PubMed ID: 25366680
[TBL] [Abstract][Full Text] [Related]
22. Incorporation of pazopanib in maintenance therapy of ovarian cancer.
du Bois A; Floquet A; Kim JW; Rau J; del Campo JM; Friedlander M; Pignata S; Fujiwara K; Vergote I; Colombo N; Mirza MR; Monk BJ; Kimmig R; Ray-Coquard I; Zang R; Diaz-Padilla I; Baumann KH; Mouret-Reynier MA; Kim JH; Kurzeder C; Lesoin A; Vasey P; Marth C; Canzler U; Scambia G; Shimada M; Calvert P; Pujade-Lauraine E; Kim BG; Herzog TJ; Mitrica I; Schade-Brittinger C; Wang Q; Crescenzo R; Harter P
J Clin Oncol; 2014 Oct; 32(30):3374-82. PubMed ID: 25225436
[TBL] [Abstract][Full Text] [Related]
23. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.
Liu JF; Barry WT; Birrer M; Lee JM; Buckanovich RJ; Fleming GF; Rimel B; Buss MK; Nattam S; Hurteau J; Luo W; Quy P; Whalen C; Obermayer L; Lee H; Winer EP; Kohn EC; Ivy SP; Matulonis UA
Lancet Oncol; 2014 Oct; 15(11):1207-14. PubMed ID: 25218906
[TBL] [Abstract][Full Text] [Related]
24. Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study.
Burger RA; Brady MF; Bookman MA; Monk BJ; Walker JL; Homesley HD; Fowler J; Greer BE; Boente M; Fleming GF; Lim PC; Rubin SC; Katsumata N; Liang SX
J Clin Oncol; 2014 Apr; 32(12):1210-7. PubMed ID: 24637999
[TBL] [Abstract][Full Text] [Related]
25. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Coleman RL; Brady MF; Herzog TJ; Sabbatini P; Armstrong DK; Walker JL; Kim BG; Fujiwara K; Tewari KS; O'Malley DM; Davidson SA; Rubin SC; DiSilvestro P; Basen-Engquist K; Huang H; Chan JK; Spirtos NM; Ashfaq R; Mannel RS
Lancet Oncol; 2017 Jun; 18(6):779-791. PubMed ID: 28438473
[TBL] [Abstract][Full Text] [Related]
26. Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer.
Haunschild CE; Tewari KS
Future Oncol; 2020 Mar; 16(7):225-246. PubMed ID: 31746224
[TBL] [Abstract][Full Text] [Related]
27. Impact of retrospective data verification to prepare the ICON6 trial for use in a marketing authorization application.
Embleton-Thirsk A; Deane E; Townsend S; Farrelly L; Popoola B; Parker J; Rustin G; Sydes M; Parmar M; Ledermann J; Kaplan R
Clin Trials; 2019 Oct; 16(5):502-511. PubMed ID: 31347385
[TBL] [Abstract][Full Text] [Related]
28. Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial.
Falchook G; Coleman RL; Roszak A; Behbakht K; Matulonis U; Ray-Coquard I; Sawrycki P; Duska LR; Tew W; Ghamande S; Lesoin A; Schwartz PE; Buscema J; Fabbro M; Lortholary A; Goff B; Kurzrock R; Martin LP; Gray HJ; Fu S; Sheldon-Waniga E; Lin HM; Venkatakrishnan K; Zhou X; Leonard EJ; Schilder RJ
JAMA Oncol; 2019 Jan; 5(1):e183773. PubMed ID: 30347019
[TBL] [Abstract][Full Text] [Related]
29. Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour.
Zhang J; Zhang Y; Tang S; Jiang L; He Q; Hamblin LT; He J; Xu Z; Wu J; Chen Y; Liang H; Chen D; Huang Y; Wang X; Deng K; Jiang S; Zhou J; Xu J; Chen X; Liang W; He J
BMJ Open; 2018 Sep; 8(9):e017240. PubMed ID: 30206071
[TBL] [Abstract][Full Text] [Related]
30. Prediction of chemotherapy response in ovarian cancer patients using a new clustered quantitative image marker.
Zargari A; Du Y; Heidari M; Thai TC; Gunderson CC; Moore K; Mannel RS; Liu H; Zheng B; Qiu Y
Phys Med Biol; 2018 Aug; 63(15):155020. PubMed ID: 30010611
[TBL] [Abstract][Full Text] [Related]
31. The Role of the Insulin-Like Growth Factor 1 Pathway in Immune Tumor Microenvironment and Its Clinical Ramifications in Gynecologic Malignancies.
Yahya MA; Sharon SM; Hantisteanu S; Hallak M; Bruchim I
Front Endocrinol (Lausanne); 2018; 9():297. PubMed ID: 29922232
[TBL] [Abstract][Full Text] [Related]
32. Evaluation bias in objective response rate and disease control rate between blinded independent central review and local assessment: a study-level pooled analysis of phase III randomized control trials in the past seven years.
Zhang J; Zhang Y; Tang S; Liang H; Chen D; Jiang L; He Q; Huang Y; Wang X; Deng K; Jiang S; Zhou J; Xu J; Chen X; Liang W; He J
Ann Transl Med; 2017 Dec; 5(24):481. PubMed ID: 29299443
[TBL] [Abstract][Full Text] [Related]
33. Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer.
Aghajanian C; Goff B; Nycum LR; Wang YV; Husain A; Blank SV
Gynecol Oncol; 2015 Oct; 139(1):10-6. PubMed ID: 26271155
[TBL] [Abstract][Full Text] [Related]
34. Toward a science of tumor forecasting for clinical oncology.
Yankeelov TE; Quaranta V; Evans KJ; Rericha EC
Cancer Res; 2015 Mar; 75(6):918-23. PubMed ID: 25592148
[TBL] [Abstract][Full Text] [Related]
35. New ways to successfully target tumor vasculature in ovarian cancer.
Yang X; Shen F; Hu W; Coleman RL; Sood AK
Curr Opin Obstet Gynecol; 2015 Feb; 27(1):58-65. PubMed ID: 25502429
[TBL] [Abstract][Full Text] [Related]
36. Bevacizumab: a review of its use in advanced cancer.
Keating GM
Drugs; 2014 Oct; 74(16):1891-1925. PubMed ID: 25315029
[TBL] [Abstract][Full Text] [Related]
37. Bevacizumab in combination with gemcitabine and carboplatin in recurrent ovarian cancer: a critical consideration.
Giovannoni S; Trenta P
J Gynecol Oncol; 2014 Oct; 25(4):355-6. PubMed ID: 25310036
[No Abstract] [Full Text] [Related]
38. Independent radiologic review: bevacizumab in combination with gemcitabine and carboplatin in recurrent ovarian cancer.
Aghajanian C; Goff B; Nycum LR; Wang Y; Husain A; Blank S
Gynecol Oncol; 2014 Apr; 133(1):105-10. PubMed ID: 24508841
[TBL] [Abstract][Full Text] [Related]
39. Independent radiologic review of the Gynecologic Oncology Group Study 0218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer.
Burger RA; Brady MF; Rhee J; Sovak MA; Kong G; Nguyen HP; Bookman MA
Gynecol Oncol; 2013 Oct; 131(1):21-6. PubMed ID: 23906656
[TBL] [Abstract][Full Text] [Related]
40. Independent radiologic review of AURELIA, a phase 3 trial of bevacizumab plus chemotherapy for platinum-resistant recurrent ovarian cancer.
Husain A; Wang Y; Hanker LC; Ojeda B; Anttila M; Breda E; Vuylsteke P; Pujade-Lauraine E
Gynecol Oncol; 2016 Sep; 142(3):465-70. PubMed ID: 27184721
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
